Pharminent · Daily Brief
September 28, 2026
Regulatory & Approvals
FDA approves AbbVie’s Parkinson’s disease therapy Juvmo
AbbVie’s Parkinson’s disease therapy Juvmo has won FDA approval, the first drug from AbbVie’s $8.7 billion takeover of Cerevel two years ago.
Pharmaphorum →$ABBV
FDA approves Mirum and Incyte’s Atebrioz for FOP
The FDA approved Mirum Pharmaceuticals and Incyte’s Atebrioz (zilurgisertib) for the treatment of fibrodysplasia ossificans progressiva in patients aged 12 and above.
Pharmaceutical Technology →
Daiichi Sankyo, MSD withdraw ifinatamab deruxtecan BLA in small cell lung cancer
Daiichi Sankyo and Merck & Co (MSD) voluntarily withdrew their biologics license application for ifinatamab deruxtecan (I-DXd) in adult patients with extensive-stage small cell lung cancer.
Pharmaceutical Technology →$DSNKY$MRK
Clinical Data
Study finds nanopore sequencing could aid inherited muscle disease diagnosis
A new study suggests long-read ‘nanopore’ sequencing could transform the diagnosis of inherited diseases and unlock new insights for drug discovery.
Pharmaphorum →
Forwarded this? Get your copy free
Sign up free →
Pharminent — Competitive Intelligence Suite · Tickers link to Yahoo Finance for reference only. Editorial framings are analysis, not investment advice. © 2026.